Imo yesterdays announcement once again proves that the...

Imo yesterdays announcement once again proves that the Australian investment market continues to ignore or even acknowledge that we have entered a new era of the Bio-tech boom.

When a little known bio-spec that had previously stated they were actively exploring commercial partnerships for specialty products, e.g. percutaneous tissue heart valves announces a (reverse) take-over of unlisted cashed-up Allied Medical Ltd adorned with some celebrity names, a couple of questions remain.

Let us forget about the aquisition of Allied for a quick moment and lend some thought to the new names coming on board:

The Liberman family, estimated worth of $2.2billion

Prof Ian Frazer, (Australian of the Year 2006) and the developer of pharmaceutical Giant, Merck's US$2 Billion Gardasil cervical cancer vaccine.

Mr Twiggy Forrest, estimated worth of $US4.1 billion

Why would these people want a piece of BioMD without having confidence of much to gain?

The use of stem cells in tissue regeneration is currently one of the medical world's most exciting discoveries.

As a long term believer in BioMD's innovative technology with the use of human stem cells for tissue regeneration there has always remained a signal that stands out quite clearly imo.

Our Chairman Robert Scott told S/Holders in the 3rd quarter last year "The Board of Directors are of the opinion that the Company is nearing the commercialisation stage of its products, which will be an exciting time."

* Commercialisation partnerships being explored for specialty products, e.g. percutaneous tissue heart valves

* Australian TGA, and European CE regulatory applications filed ~ Q1,2011

* FDA application to follow TGA/CE ~ Q2, 2011

* Global Heart Valve Project Completed ~ Q2,2011

* Commercial product Cardiocel ready for AUST & ASIAN markets ~ Q2,2011

* Cardiocel patch distribution agreement for Europe ~ Q3.2011

"A growing trend in the global pharmaceutical industry in recent times has been for Big and Specialty Pharma companies to in-license or acquire emerging biotech companies as a way of battling declining pipelines, looming patent expirations, a slowdown in drug spending growth in major Western markets, and the rising costs of drug development. The pharma companies are also increasingly interested in positioning themselves to benefit from the increasing popularity of biological and bio-type products as against traditional small molecules.